These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

523 related items for PubMed ID: 16844231

  • 1. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments.
    Kang TH, Lee JH, Bae HC, Noh KH, Kim JH, Song CK, Shin BC, Hung CF, Wu TC, Park JS, Kim TW.
    Immunol Lett; 2006 Aug 15; 106(2):126-34. PubMed ID: 16844231
    [Abstract] [Full Text] [Related]

  • 2. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors.
    Ji H, Wang TL, Chen CH, Pai SI, Hung CF, Lin KY, Kurman RJ, Pardoll DM, Wu TC.
    Hum Gene Ther; 1999 Nov 20; 10(17):2727-40. PubMed ID: 10584920
    [Abstract] [Full Text] [Related]

  • 3. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments.
    Cheng WF, Hung CF, Hsu KF, Chai CY, He L, Ling M, Slater LA, Roden RB, Wu TC.
    Hum Gene Ther; 2001 Feb 10; 12(3):235-52. PubMed ID: 11177561
    [Abstract] [Full Text] [Related]

  • 4. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death.
    Kim JH, Kang TH, Noh KH, Bae HC, Kim SH, Yoo YD, Seong SY, Kim TW.
    Immunol Lett; 2009 Jan 29; 122(1):58-67. PubMed ID: 19135479
    [Abstract] [Full Text] [Related]

  • 5. Comparison of HPV DNA vaccines employing intracellular targeting strategies.
    Kim JW, Hung CF, Juang J, He L, Kim TW, Armstrong DK, Pai SI, Chen PJ, Lin CT, Boyd DA, Wu TC.
    Gene Ther; 2004 Jun 29; 11(12):1011-8. PubMed ID: 14985791
    [Abstract] [Full Text] [Related]

  • 6. Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments.
    Kang TH, Lee JH, Noh KH, Han HD, Shin BC, Choi EY, Peng S, Hung CF, Wu TC, Kim TW.
    Int J Cancer; 2007 Apr 15; 120(8):1696-703. PubMed ID: 17230516
    [Abstract] [Full Text] [Related]

  • 7. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
    Park JY, Jin DH, Lee CM, Jang MJ, Lee SY, Shin HS, Chung YH, Kim KY, Kim SS, Lee WB, Shin YK, Lee WJ, Park YM, Kim D.
    J Immunother; 2010 Jun 15; 33(5):510-22. PubMed ID: 20463596
    [Abstract] [Full Text] [Related]

  • 8. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection.
    Brulet JM, Maudoux F, Thomas S, Thielemans K, Burny A, Leo O, Bex F, Hallez S.
    Eur J Immunol; 2007 Feb 15; 37(2):376-84. PubMed ID: 17274002
    [Abstract] [Full Text] [Related]

  • 9. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model.
    Tillman BW, Hayes TL, DeGruijl TD, Douglas JT, Curiel DT.
    Cancer Res; 2000 Oct 01; 60(19):5456-63. PubMed ID: 11034088
    [Abstract] [Full Text] [Related]

  • 10. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells.
    De Bruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, de Cock KA, Ooms ME, Ressing ME, Toebes M, Franken KL, Drijfhout JW, Ottenhoff TH, Offringa R, Melief CJ.
    Cancer Res; 1998 Feb 15; 58(4):724-31. PubMed ID: 9485027
    [Abstract] [Full Text] [Related]

  • 11. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines.
    Hauser H, Shen L, Gu QL, Krueger S, Chen SY.
    Gene Ther; 2004 Jun 15; 11(11):924-32. PubMed ID: 15085173
    [Abstract] [Full Text] [Related]

  • 12. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
    Hsieh CJ, Kim TW, Hung CF, Juang J, Moniz M, Boyd DA, He L, Chen PJ, Chen CH, Wu TC.
    Vaccine; 2004 Sep 28; 22(29-30):3993-4001. PubMed ID: 15364449
    [Abstract] [Full Text] [Related]

  • 13. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
    Huang CY, Chen CA, Lee CN, Chang MC, Su YN, Lin YC, Hsieh CY, Cheng WF.
    Gynecol Oncol; 2007 Dec 28; 107(3):404-12. PubMed ID: 17905417
    [Abstract] [Full Text] [Related]

  • 14. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.
    Chen CH, Wang TL, Ji H, Hung CF, Pardoll DM, Cheng WF, Ling M, Wu TC.
    Gene Ther; 2001 Jan 28; 8(2):128-38. PubMed ID: 11313782
    [Abstract] [Full Text] [Related]

  • 15. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
    Yin R, Zheng W, Hao F, Yang XC, Zhong BY, Li QJ.
    J Dermatol Sci; 2009 Aug 28; 55(2):116-22. PubMed ID: 19500947
    [Abstract] [Full Text] [Related]

  • 16. Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies.
    Peng S, Trimble C, Ji H, He L, Tsai YC, Macaes B, Hung CF, Wu TC.
    J Biomed Sci; 2005 Oct 28; 12(5):689-700. PubMed ID: 16200349
    [Abstract] [Full Text] [Related]

  • 17. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs.
    Chen CH, Ji H, Suh KW, Choti MA, Pardoll DM, Wu TC.
    Gene Ther; 1999 Dec 28; 6(12):1972-81. PubMed ID: 10637448
    [Abstract] [Full Text] [Related]

  • 18. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity.
    Wang TL, Ling M, Shih IM, Pham T, Pai SI, Lu Z, Kurman RJ, Pardoll DM, Wu TC.
    Gene Ther; 2000 May 28; 7(9):726-33. PubMed ID: 10822298
    [Abstract] [Full Text] [Related]

  • 19. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
    Singh SK, Stephani J, Schaefer M, Kalay H, García-Vallejo JJ, den Haan J, Saeland E, Sparwasser T, van Kooyk Y.
    Mol Immunol; 2009 Dec 28; 47(2-3):164-74. PubMed ID: 19818504
    [Abstract] [Full Text] [Related]

  • 20. DNA vaccines employing intracellular targeting strategies and a strategy to prolong dendritic cell life generate a higher number of CD8+ memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen.
    Kim TW, Lee JH, He L, Boyd DA, Hung CF, Wu TC.
    Hum Gene Ther; 2005 Jan 28; 16(1):26-34. PubMed ID: 15703486
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.